A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Varian, a Siemens Healthineers Company
Travera Inc
Nammi Therapeutics Inc
Revolution Medicines, Inc.
AstraZeneca
Conjupro Biotherapeutics, Inc.
Whitehawk Therapeutics, Inc.
SystImmune Inc.
Filamon LTD
On Target Laboratories, LLC
PMV Pharmaceuticals, Inc
Convalife (Shanghai) Co., Ltd.
ViroMissile, Inc.
Carevive Systems, Inc.
A2 Biotherapeutics Inc.
Tizona Therapeutics, Inc
Clasp Therapeutics, Inc.
New Phase Ltd.
Revolution Medicines, Inc.
SystImmune Inc.
Pheon Therapeutics
Daiichi Sankyo
EXoPERT
Adela, Inc
Natera, Inc.
Second Life Therapeutics
Eli Lilly and Company
Seagen Inc.
Varian, a Siemens Healthineers Company
Novartis
Dysplasia Diagnostics Limited
Elephas
Seagen Inc.
Degron Therapeutics Co.
Shasqi, Inc.
Tempus AI
Massive Bio, Inc.
Chongqing Precision Biotech Co., Ltd
LigaChem Biosciences, Inc.
Shanghai Escugen Biotechnology Co., Ltd
Incyte Corporation
Novartis
Novita Pharmaceuticals, Inc.
Marengo Therapeutics, Inc.
Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc.
Compugen Ltd
Monopar Therapeutics
Monopar Therapeutics